CD4 and tuberculosis: Several studies have found that earlier ART initiation for patients with CD4 between 200 and 350 decreases rates of death, disease progression and incident tuberculosis while increasing retention in care and virologic suppression, among newly eligible patients in both trial 5, 22 and non‐trial settings 6, 8, 23, 24, 25, 26.